Browse News
Filter News
Found 78 articles
-
This week's research roundup includes studies involving Crohn's disease, myocarditis, COVID-19, a potential cure for childhood brain tumors and more.
-
Novavax released its second quarter financial results, showing a dramatic adjustment in its sales outlook, while BioNTech prepares to launch two variant-adopted bivalent shots.
-
COVID-19 Update: BA.4 and BA.5 Dominate, Long COVID Effects Continue, CDC Considers Novavax
7/19/2022
As the BA.4/BA.5 Omicron subvariants spread, researchers continue to develop COVID-19 therapies and approaches for preventing or treating the disease. For that and more, continue reading. -
The FDA granted Novavax’s COVID-19 vaccine Emergency Use Authorization after a lengthy and obstacle-riddled journey. It is authorized as a two-dose primary series for adults 18 years and older.
-
Millions of COVID-19 Shots Discarded, while Intermittent Fasting Could Curb Serious Disease
7/8/2022
With COVID-19 vaccination rates dropping, millions of doses are going to waste. Meanwhile, outdoors isn't sure-fire protection but long-term intermittent fasters may be spared severe disease. -
There’s quite a bit of movement on the Omicron-specific booster shot and updated supply deals, despite world leaders shifting their attention away from the COVID-19 pandemic.
-
Thursday, a committee of advisors for the CDC voted unanimously for children and teens, ages six to 17 to receive Moderna's COVID-19 vaccine.
-
Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age
6/17/2022
Today, the U.S. Food and Drug Administration authorized emergency use of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 to include use in children down to 6 months of age.
-
Moderna's study, dubbed BabyCove, is expected to begin recruiting in September and will include up to 700 babies three to six months of age.
-
UPDATE: In Unanimous Vote, FDA Advisory Committee Recommends Moderna's COVID Vaccine for Kids 6-17
6/14/2022
In a unanimous vote, a panel of FDA advisors voted to recommend the approval of Moderna's COVID-19 vaccine for children between the ages of six and 17 years old. -
On Tuesday, the FDA's Vaccines and Related Biological Products Advisory Committee voted 21-0 with one abstention to recommend authorization of Novavax’s COVID-19 vaccine.
-
The FDA has expressed worries over four cases of heart inflammation, or myocarditis, that were observed in pivotal clinical trials of Novavax's COVID-19 vaccine.
-
COVID-19 vaccines are the most-studied vaccines in history. This is partly why some data can appear so contradictory. For those and more COVID-19 stories, continue reading.
-
Moderna reported positive interim results from the Phase II/III KidCOVE trial of its mRNA COVID-19 vaccine for children six months to under two years and two to six years of age.
-
There is some evidence that COVID-19 infection might be linked to an increase in diabetes, particularly Type 1 diabetes, which is an autoimmune disease most commonly diagnosed in children.
-
At this time, 73% of Americans are immune to Omicron, and it could rise to 80% by mid-March. For that and more COVID-19 news, continue reading.
-
Research Roundup for February 4
-
Clinical trial news definitely picked up this final week of January. Here’s a look.
-
Coronavirus (COVID-19) Update: FDA Takes Key Action by Approving Second COVID-19 Vaccine
1/31/2022
Today, the U.S. Food and Drug Administration approved a second COVID-19 vaccine. The vaccine has been known as the Moderna COVID-19 Vaccine; the approved vaccine will be marketed as Spikevax for the prevention of COVID-19 in individuals 18 years of age and older.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.